Chimerix, Inc. (CMRX) Stake Boosted by Bank of New York Mellon Corp

Bank of New York Mellon Corp grew its stake in shares of Chimerix, Inc. (NASDAQ:CMRX) by 3.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 253,367 shares of the biopharmaceutical company’s stock after acquiring an additional 8,287 shares during the quarter. Bank of New York Mellon Corp owned about 0.54% of Chimerix worth $1,381,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. FMR LLC increased its holdings in shares of Chimerix by 0.5% during the first quarter. FMR LLC now owns 6,979,429 shares of the biopharmaceutical company’s stock valued at $44,529,000 after acquiring an additional 36,016 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Chimerix by 13.1% during the first quarter. Vanguard Group Inc. now owns 1,848,257 shares of the biopharmaceutical company’s stock valued at $11,792,000 after acquiring an additional 213,894 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Chimerix by 114.9% during the first quarter. Dimensional Fund Advisors LP now owns 1,043,336 shares of the biopharmaceutical company’s stock valued at $6,656,000 after acquiring an additional 557,927 shares in the last quarter. Morgan Stanley increased its holdings in shares of Chimerix by 203.9% during the first quarter. Morgan Stanley now owns 618,074 shares of the biopharmaceutical company’s stock valued at $3,944,000 after acquiring an additional 414,717 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Chimerix by 11.7% during the first quarter. Geode Capital Management LLC now owns 341,238 shares of the biopharmaceutical company’s stock valued at $2,177,000 after acquiring an additional 35,752 shares in the last quarter. Hedge funds and other institutional investors own 67.53% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Chimerix, Inc. (CMRX) Stake Boosted by Bank of New York Mellon Corp” was posted by Stock Observer and is the sole property of of Stock Observer. If you are accessing this article on another site, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this article can be read at https://www.thestockobserver.com/2017/10/21/chimerix-inc-cmrx-stake-boosted-by-bank-of-new-york-mellon-corp.html.

Several equities analysts have recently issued reports on CMRX shares. Zacks Investment Research downgraded shares of Chimerix from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. ValuEngine downgraded shares of Chimerix from a “sell” rating to a “strong sell” rating in a report on Monday, September 18th.

Chimerix, Inc. (NASDAQ CMRX) opened at 5.07 on Friday. Chimerix, Inc. has a 12-month low of $3.66 and a 12-month high of $6.64. The firm’s market cap is $238.52 million. The stock’s 50 day moving average is $5.11 and its 200 day moving average is $5.10.

Chimerix (NASDAQ:CMRX) last released its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.05. The company had revenue of $0.68 million for the quarter, compared to analyst estimates of $1.28 million. Chimerix had a negative return on equity of 24.68% and a negative net margin of 1,514.27%. On average, equities research analysts expect that Chimerix, Inc. will post ($1.63) EPS for the current year.

About Chimerix

Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.

Institutional Ownership by Quarter for Chimerix (NASDAQ:CMRX)

Receive News & Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply